GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (STU:26CA) » Definitions » EBITDA Margin %

ImmunityBio (STU:26CA) EBITDA Margin % : -228,975.68% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ImmunityBio's EBITDA for the three months ended in Mar. 2024 was €-84.72 Mil. ImmunityBio's Revenue for the three months ended in Mar. 2024 was €0.04 Mil. Therefore, ImmunityBio's EBITDA margin for the quarter that ended in Mar. 2024 was -228,975.68%.


ImmunityBio EBITDA Margin % Historical Data

The historical data trend for ImmunityBio's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio EBITDA Margin % Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
-6,370.89 -33,776.46 -34,324.79 -139,525.11 -70,171.75

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22,817.86 -246,042.11 -68,189.61 -142,073.23 -228,975.68

Competitive Comparison of ImmunityBio's EBITDA Margin %

For the Biotechnology subindustry, ImmunityBio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmunityBio's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunityBio's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ImmunityBio's EBITDA Margin % falls into.



ImmunityBio EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ImmunityBio's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-399.979/0.57
=-70,171.75 %

ImmunityBio's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-84.721/0.037
=-228,975.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunityBio  (STU:26CA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


ImmunityBio EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of ImmunityBio's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunityBio (STU:26CA) Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

ImmunityBio (STU:26CA) Headlines

No Headlines